In this Application Highlight we discuss:



More about this Application Highlight
MS is a complex disease that varies dramatically between individuals, and MS patients benefit from early diagnosis and a multifaceted therapeutic approach that slows disease progression and tries to reduce the number and severity of attacks.
Download this App Highlight to learn how IsoPlexis was used to identify a pathologically and therapeutically relevant Toll-like receptor (TLR) previously uncharacterized in MS and to prove the hypothesis that MS patients have a deficiency in innate immune regulation leading to hyper-responsiveness to TLR2 stimulation.

